The Diagnostic Value of Multiparametric-MRI in Locating Prostate Cancer for Transrectal Ultrasound-Guided Biopsy
-
Sayed Mohammad Sakhaei
,
Sedighe Rahmani Firouzabadi
,
Mohamad Ghazanfari Hashemi
,
Seyedeh Nooshin Miratashi Yazdi
,
Mohammad Ali Kaviani
,
Maryam Alaei
,
Helia Helali
,
Maedeh Ghazanfari Hashemi
,
Marjan Gholami
,
Vahid Talebi
Abstract
Purpose: The present study was designed to evaluate the potential efficacy of Multiparametric-Magnetic Resonance Imaging (MP-MRI) in the detection of prostate cancer locations compared to Transrectal Ultrasound (TRUS) guided biopsy, as the gold standard method.
Materials and Methods: A total of 66 subjects participated in this cross-sectional study. All individuals underwent MP-MRI imaging before the prostate TRUS. The findings of either method have been investigated and the comparison had been made using the Chi-squared test.
Results: The sensitivity and specificity of the MP-MRI in the diagnosis of prostate cancer were 81.8% and 93.9%, respectively. The positive and negative predictive values were 93.1% and 83.8%, respectively.
Conclusion: The current study indicates that the MP-MRI imaging method has sufficient sensitivity and specificity for detecting the location of prostate cancer and can potentially be employed as a clue-providing method prior to the TRUS-guided biopsy.
[1] M. Daniyal, Z. A. Siddiqui, M. Akram, H. M. Asif, S. Sultana, and A. Khan, “Epidemiology, etiology, diagnosis and treatment of prostate cancer,” Asian Pac. J. Cancer Prev., vol. 15, no. 22, pp. 9575–9578, 2014, doi: 10.7314/APJCP.2014.15.22.9575.
[2] W. J. Catalona, “Prostate Cancer Screening,” Med. Clin. North Am., vol. 102, no. 2, pp. 199–214, Mar. 2018, doi: 10.1016/J.MCNA.2017.11.001.
[3] M. S. Litwin and H. J. Tan, “The Diagnosis and Treatment of Prostate Cancer: A Review,” JAMA, vol. 317, no. 24, pp. 2532–2542, Jun. 2017, doi: 10.1001/JAMA.2017.7248.
[4] A. Stabile et al., “Multiparametric MRI for prostate cancer diagnosis: current status and future directions,” Nat. Rev. Urol., vol. 17, no. 1, pp. 41–61, Jan. 2020, doi: 10.1038/S41585-019-0212-4.
[5] B. Djavan et al., “PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL,” Urology, vol. 54, no. 3, pp. 517–522, Sep. 1999, doi: 10.1016/S0090-4295(99)00153-3.
[6] K. L et al., “Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis,” Can. Urol. Assoc. J., vol. 15, no. 1, pp. E11–E16, Jul. 2021, doi: 10.5489/CUAJ.6712.
[7] H. U. Ahmed et al., “Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study,” Lancet (London, England), vol. 389, no. 10071, pp. 815–822, Feb. 2017, doi: 10.1016/S0140-6736(16)32401-1.
[8] H. J. Meyer, A. Wienke, and A. Surov, “Can dynamic contrast enhanced MRI predict gleason score in prostate cancer? a systematic review and meta analysis,” Urol. Oncol., vol. 39, no. 11, pp. 784.e17-784.e25, Nov. 2021, doi: 10.1016/J.UROLONC.2021.03.015.
[9] B. Turkbey et al., “Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2,” Eur. Urol., vol. 76, no. 3, pp. 340–351, Sep. 2019, doi: 10.1016/J.EURURO.2019.02.033.
[10] T. Franiel et al., “MRI of the Prostate: Recommendations on Patient Preparation and Scanning Protocol,” Rofo, vol. 189, no. 1, pp. 21–28, Jan. 2017, doi: 10.1055/S-0042-119451.
[11] T. Franiel, P. Asbach, U. Teichgräber, B. Hamm, and S. Foller, “Prostate Imaging--An Update,” Rofo, vol. 187, no. 9, pp. 751–759, Sep. 2015, doi: 10.1055/S-0035-1553162.
[12] M. Rafiq, F. Farag, K. Manley, and E. Ho, “Ciprofloxacin: single versus multiple doses in transrectal ultrasound guided prostate biopsy,” Cent. Eur. J. Urol., vol. 73, no. 1, pp. 91–93, 2020, doi: 10.5173/CEJU.2020.0067.
[13] J. E. Lee, S. S. Shin, T. W. Kang, J. W. Kim, S. H. Heo, and Y. Y. Jeong, “Comparison of Different Rectal Cleansing Methods for Reducing Post-Procedural Infectious Complications After Transrectal Ultrasound-Guided Prostate Biopsy,” Urol. J., vol. 17, no. 1, pp. 42–49, Jan. 2020, doi: 10.22037/UJ.V0I0.4583.
[14] M. S. Lee, M. H. Moon, C. K. Kim, S. Y. Park, M. H. Choi, and S. Il Jung, “Guidelines for Transrectal Ultrasonography-Guided Prostate Biopsy: Korean Society of Urogenital Radiology Consensus Statement for Patient Preparation, Standard Technique, and Biopsy-Related Pain Management,” Korean J. Radiol., vol. 21, no. 4, pp. 422–430, Apr. 2020, doi: 10.3348/KJR.2019.0576.
[15] C. J. Das, A. Razik, S. Sharma, and S. Verma, “Prostate biopsy: when and how to perform,” Clin. Radiol., vol. 74, no. 11, pp. 853–864, Nov. 2019, doi: 10.1016/J.CRAD.2019.03.016.
[16] A. Lopez-Beltran, G. Mikuz, R. J. Luque, R. Mazzucchelli, and R. Montironi, “Current practice of Gleason grading of prostate carcinoma,” Virchows Arch., vol. 448, no. 2, pp. 111–118, Feb. 2006, doi: 10.1007/S00428-005-0102-4.
[17] D. C. Johnson et al., “Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging,” Eur. Urol., vol. 75, no. 5, pp. 712–720, May 2019, doi: 10.1016/J.EURURO.2018.11.031.
[18] J. S. Wysock et al., “Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results,” BJU Int., vol. 118, no. 4, pp. 515–520, Oct. 2016, doi: 10.1111/BJU.13427.
[19] M. De Rooij, E. H. J. Hamoen, J. J. Fütterer, J. O. Barentsz, and M. M. Rovers, “Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis,” AJR. Am. J. Roentgenol., vol. 202, no. 2, pp. 343–351, Feb. 2014, doi: 10.2214/AJR.13.11046.
[20] C. E. Lovegrove et al., “Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial,” J. Urol., vol. 203, no. 1, pp. 100–107, Jan. 2020, doi: 10.1097/JU.0000000000000455.
[21] A. Sivaraman et al., “Transperineal template-guided mapping biopsy of the prostate,” Int. J. Urol., vol. 22, no. 2, pp. 146–151, Feb. 2015, doi: 10.1111/IJU.12660.
[2] W. J. Catalona, “Prostate Cancer Screening,” Med. Clin. North Am., vol. 102, no. 2, pp. 199–214, Mar. 2018, doi: 10.1016/J.MCNA.2017.11.001.
[3] M. S. Litwin and H. J. Tan, “The Diagnosis and Treatment of Prostate Cancer: A Review,” JAMA, vol. 317, no. 24, pp. 2532–2542, Jun. 2017, doi: 10.1001/JAMA.2017.7248.
[4] A. Stabile et al., “Multiparametric MRI for prostate cancer diagnosis: current status and future directions,” Nat. Rev. Urol., vol. 17, no. 1, pp. 41–61, Jan. 2020, doi: 10.1038/S41585-019-0212-4.
[5] B. Djavan et al., “PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL,” Urology, vol. 54, no. 3, pp. 517–522, Sep. 1999, doi: 10.1016/S0090-4295(99)00153-3.
[6] K. L et al., “Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis,” Can. Urol. Assoc. J., vol. 15, no. 1, pp. E11–E16, Jul. 2021, doi: 10.5489/CUAJ.6712.
[7] H. U. Ahmed et al., “Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study,” Lancet (London, England), vol. 389, no. 10071, pp. 815–822, Feb. 2017, doi: 10.1016/S0140-6736(16)32401-1.
[8] H. J. Meyer, A. Wienke, and A. Surov, “Can dynamic contrast enhanced MRI predict gleason score in prostate cancer? a systematic review and meta analysis,” Urol. Oncol., vol. 39, no. 11, pp. 784.e17-784.e25, Nov. 2021, doi: 10.1016/J.UROLONC.2021.03.015.
[9] B. Turkbey et al., “Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2,” Eur. Urol., vol. 76, no. 3, pp. 340–351, Sep. 2019, doi: 10.1016/J.EURURO.2019.02.033.
[10] T. Franiel et al., “MRI of the Prostate: Recommendations on Patient Preparation and Scanning Protocol,” Rofo, vol. 189, no. 1, pp. 21–28, Jan. 2017, doi: 10.1055/S-0042-119451.
[11] T. Franiel, P. Asbach, U. Teichgräber, B. Hamm, and S. Foller, “Prostate Imaging--An Update,” Rofo, vol. 187, no. 9, pp. 751–759, Sep. 2015, doi: 10.1055/S-0035-1553162.
[12] M. Rafiq, F. Farag, K. Manley, and E. Ho, “Ciprofloxacin: single versus multiple doses in transrectal ultrasound guided prostate biopsy,” Cent. Eur. J. Urol., vol. 73, no. 1, pp. 91–93, 2020, doi: 10.5173/CEJU.2020.0067.
[13] J. E. Lee, S. S. Shin, T. W. Kang, J. W. Kim, S. H. Heo, and Y. Y. Jeong, “Comparison of Different Rectal Cleansing Methods for Reducing Post-Procedural Infectious Complications After Transrectal Ultrasound-Guided Prostate Biopsy,” Urol. J., vol. 17, no. 1, pp. 42–49, Jan. 2020, doi: 10.22037/UJ.V0I0.4583.
[14] M. S. Lee, M. H. Moon, C. K. Kim, S. Y. Park, M. H. Choi, and S. Il Jung, “Guidelines for Transrectal Ultrasonography-Guided Prostate Biopsy: Korean Society of Urogenital Radiology Consensus Statement for Patient Preparation, Standard Technique, and Biopsy-Related Pain Management,” Korean J. Radiol., vol. 21, no. 4, pp. 422–430, Apr. 2020, doi: 10.3348/KJR.2019.0576.
[15] C. J. Das, A. Razik, S. Sharma, and S. Verma, “Prostate biopsy: when and how to perform,” Clin. Radiol., vol. 74, no. 11, pp. 853–864, Nov. 2019, doi: 10.1016/J.CRAD.2019.03.016.
[16] A. Lopez-Beltran, G. Mikuz, R. J. Luque, R. Mazzucchelli, and R. Montironi, “Current practice of Gleason grading of prostate carcinoma,” Virchows Arch., vol. 448, no. 2, pp. 111–118, Feb. 2006, doi: 10.1007/S00428-005-0102-4.
[17] D. C. Johnson et al., “Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging,” Eur. Urol., vol. 75, no. 5, pp. 712–720, May 2019, doi: 10.1016/J.EURURO.2018.11.031.
[18] J. S. Wysock et al., “Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results,” BJU Int., vol. 118, no. 4, pp. 515–520, Oct. 2016, doi: 10.1111/BJU.13427.
[19] M. De Rooij, E. H. J. Hamoen, J. J. Fütterer, J. O. Barentsz, and M. M. Rovers, “Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis,” AJR. Am. J. Roentgenol., vol. 202, no. 2, pp. 343–351, Feb. 2014, doi: 10.2214/AJR.13.11046.
[20] C. E. Lovegrove et al., “Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial,” J. Urol., vol. 203, no. 1, pp. 100–107, Jan. 2020, doi: 10.1097/JU.0000000000000455.
[21] A. Sivaraman et al., “Transperineal template-guided mapping biopsy of the prostate,” Int. J. Urol., vol. 22, no. 2, pp. 146–151, Feb. 2015, doi: 10.1111/IJU.12660.
| Files | ||
| Issue | Vol 11 No 2 (2024) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/fbt.v11i2.15334 | |
| Keywords | ||
| Prostate Cancer Magnetic Resonance Imaging Ultrasound Biopsy | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Sakhaei SM, Rahmani Firouzabadi S, Ghazanfari Hashemi M, Miratashi Yazdi SN, Kaviani MA, Alaei M, Helali H, Ghazanfari Hashemi M, Gholami M, Talebi V. The Diagnostic Value of Multiparametric-MRI in Locating Prostate Cancer for Transrectal Ultrasound-Guided Biopsy. Frontiers Biomed Technol. 2024;11(2):184-190.
